Key Highlights

  • ILMN shares trading down 14.12% today to $249.09, implying a prior close near $290.
  • Illumina scheduled its third-quarter results for Oct. 29, with consensus at $1.36 per share and $1.15 billion in revenue.
  • Second-quarter Earnings of $1.31 per share beat the $1.23 consensus on Revenue of $1.16 billion.
  • Full-year earnings guidance from July was $5.30 to $5.40 per share.
  • The 52-week range was $94.00 to $309.35 as of Oct. 26, with a market Capitalization of $40.93 billion.

Illumina Falls From Above $290 in the Session After Its Third-Quarter Report

Illumina (NASDAQ:ILMN) shares are trading down 14.12% today at $249.09, which implies a prior close of roughly $290. The company had scheduled its third-quarter 2026 financial results for Thursday, Oct. 29. The specific figures and guidance changes behind today's reaction could not be confirmed from the sources reviewed, so the exact trigger is not stated here.

Market estimates ahead of the report called for earnings of $1.36 per share on revenue of $1.15 billion. Before the move, the stock had closed at $271.04 on Oct. 26 and was up about 0.6% that day, with a 52-week high of $309.35.

A Second-Quarter Beat and $5.30 to $5.40 Earnings Guidance Set a High Bar

At its July 30 report, Illumina posted second-quarter earnings of $1.31 per share against a $1.23 consensus, with revenue of $1.16 billion versus $1.13 billion expected. Full-year earnings guidance stood at $5.30 to $5.40 per share. Trailing twelve-month revenue was $4.49 billion, up 4.9%.

The company supplies DNA sequencing and array technology, and has been expanding software. It launched its BioInsight Platform on Oct. 14 for genomic and multiomic data, and added DRAGEN Ultra software in early access about a week later. It also set up an unsecured Commercial Paper program of up to $1.0 billion.

Stephens Downgrade and a 50 Times Earnings Multiple Preceded the Pullback

Stephens lowered its rating to Equal Weight from Overweight around Oct. 24 with a $275 price target, and Evercore removed Illumina from its Core Ideas list. Canaccord raised its target to $300 from $205, while Bank of America kept an Underperform rating with a $168 target. Across 21 analysts, the consensus was Hold with an average target of $248.90.

At $271.04, the shares carried a trailing price-to-earnings ratio of 50.47 and a forward ratio of 47.58. The 52-week low of $94.00 shows how far the stock had climbed before today's drop. Those figures were measured before the latest decline.

The stock had been volatile into the report. It rose 5.57% to $282.86 on Oct. 21 and then slid 4.76% to $269.40 the following day, before settling near $270 through Oct. 26. Bank of America had lifted its target to $168 around Oct. 10, though the rating stayed at Underperform, leaving that target far below the Market Price at the time.

Third-Quarter Details and BioInsight Rollout Are the Next Items to Follow

Today's slide erases a sizable part of the recent advance, and the stock is now trading near the average analyst target of $248.90. The company's Oct. 29 results release and quarterly filing should clarify revenue, margins and any change to full-year earnings guidance. Investors will also track early-access adoption of the BioInsight Platform and whether analysts revise targets after the report. The company's first-quarter and second-quarter trends, including the $1.16 billion in second-quarter revenue, provide the baseline for comparison.